The US Food and Drug Administration (FDA) has granted approval for Obalon Therapeutics’ new nonsurgical and fully-reversible balloon system for weight loss.

Obalon balloon system is a nonsurgical, fully-reversible, swallowable intragastric device that will be temporarily used to facilitate weight loss in adults with obesity (BMI of 30 – 40kg/m²).

The company noted that the system will be used as an adjunct to a moderate intensity diet and behavior modification programme.

“We’re excited to bring this novel technology to the approximately 70 million adults in the United States who are struggling with obesity.”

The system includes a balloon folded inside a capsule, which is swallowed by the patient, it requires no sedation or anesthesia.

After reaching the stomach, the balloon will be remotely inflated with gas through a micro-catheter, which is then removed by leaving the lightweight and buoyant balloon in the stomach.

Two additional balloons are swallowed and inflated over the next three months of treatment. All three balloons are removed through an outpatient endoscopy under conscious sedation at the end of the six-month treatment period.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company carried out a randomised, double-blind and sham-controlled clinical trial which included 387 patients across 15 sites in the US.

In the trial, the patients received either three Obalon balloons or three sham placebo-like devices that looked similar to the balloons, but were filled with sugar.

The company intends to report the results of the study at Obesity Week later this year in New Orleans.

Obalon CEO Andy Rasdal said: “We’re excited to bring this novel technology to the approximately 70 million adults in the United States who are struggling with obesity.

“For physicians, we believe that the Obalon technology represents an important new option for both their practices and their patients who are obese and looking to lose weight.”

The company noted that the system is expected to be available in early next year to physicians who complete the Obalon Balloon System training programme.